SC IL-1Ra in SAH - Phase III Trial (SCIL) (SCIL)

  • STATUS
    Recruiting
  • End date
    Sep 4, 2024
  • participants needed
    1000
  • sponsor
    University of Manchester
Updated on 4 June 2022
withdrawn

Summary

This phase III trial will establish whether IL-1Ra, with sub-cutaneous (SC) administration twice daily for up to 21 days post aneurysmal subarachnoid haemorrhage (aSAH), improves clinical outcome as measured by ordinal shift in mRS at 6 months.

Patients with SAH transferred to a neurosurgical centre will be identified and approached for study participation. Following consent, patients will be randomised to receive either IL-1Ra or placebo for a maximum of 21 days from onset of symptoms. Patients who are found to be non-aneurysmal following randomisation will be withdrawn from the study treatment. Blood samples for plasma IL-6 will be obtained prior to randomisation and at day 3-5 post randomisation for IL-6 & IL-1 measurement. Safety will be measured at 30 days post randomisation and outcome assessed at 6 months post randomisation.

Details
Condition Subarachnoid Hemorrhage
Treatment IL-1Ra, IL-1Ra Placebo
Clinical Study IdentifierNCT03249207
SponsorUniversity of Manchester
Last Modified on4 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with CT positive spontaneous SAH admitted to a participating neurosurgical centre where written informed consent can be obtained and study drug can be administered within 72 hours of ictus
No concomitant health problems that, in the opinion of the PI or designee, would interfere with participation, administration of study drug or assessment of outcomes including safety
Willing and able to give informed consent or consent available from a patient representative for trial inclusion including agreement in principle to receive study drug and undergo all study assessments
Male or female aged 18 years or above

Exclusion Criteria

Unconfirmed or uncertain diagnosis of spontaneous SAH
Known active tuberculosis or active hepatitis
Known active malignancy
Neutropenia (ANC <1.5 x 109/L )
Known Still's Disease
Abnormal renal function (creatinine clearance or estimated Glomerular Filtration Rate (eGFR) < 30 ml/minute) documented in the last 3 months prior to this SAH
Live vaccinations within the last 10 days of this SAH
Previous or concurrent treatment with IL-1Ra known at the time of trial entry or previous participation in this trial
Current treatment with TNF antagonists
Known to be pregnant or breast feeding or inability to reliably confirm that the patient is not pregnant
Known to have participated in a clinical trial of an investigational agent or device in the 30 days prior to ictus
Clinically significant serious concurrent medical condition, pre morbid illnesses, or concurrent serious infection, at the PI's (or designee's) discretion, which could affect the safety or tolerability of the intervention
Known to have participated in a clinical trial of an investigational agent or device within 5 half-lives (of the previous agent or device) prior to ictus
Known allergy to IL-1Ra or any of the excipients listed in the drug SmPC
Known allergy to other products that are produced by DNA technology using the micro-organism E. coli (e.g. E.coli derived protein)
Current treatment with IL-6 or IL-1 inhibitors or drugs affecting the IL-1 axis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note